Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEMIA: Multi-product PrEP Delivery to Young Women
NCT07076043Phase 4Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: PrEP initiation at 6 months. Started Jun 2025; status: recruiting.
02
Drugs
dapivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07076043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076043.